Flores Jose M, Henriquez Ignacio, Jue Joshua S, Benfante Nicole, Sheinfeld Joel, Matulewicz Richard S, Mulhall John P
Sexual & Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Sexual & Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Urology. 2025 May;199:90-94. doi: 10.1016/j.urology.2024.12.005. Epub 2024 Dec 16.
To evaluate outcomes of onco-testis sperm extraction (TESE) and to define potential predictors of successful surgical sperm retrieval (SSR).
For this study, we examined all men (i) diagnosed with a testicular mass, (ii) who had azoospermia, and (iii) who underwent a radical orchiectomy and onco-TESE. Our institutional database of testicular cancer (TCA) patients was reviewed. Demographics, baseline endocrine and oncological characteristics, and treatments received were recorded. The onco-TESE Technique was performed at the time of radical orchiectomy before the specimen was sent for formal histopathological assessment. Onco-TESE was considered successful if viable sperm was found. Logistic regression assessments were performed to evaluate predictors of successful onco-TESE.
Thirty-eight men with a median age of 35 were included in the analysis. Median baseline total testosterone, LH, and FSH levels were 419ng/dL, 10.9mU/mL, and 27mU/mL, respectively. The median pre-TESE testicular volume was 11 mL. Of men who underwent radical orchiectomy, 58% had unilateral tumors at the time of the procedure. 42% had bilateral tumors, which were synchronous in 25%, and asynchronous tumors in 75%. Pathologically, 76% had germ cell tumor (83% had pure seminoma, and 17% had mixed germ cell tumor). At onco-TESE, 24% of the patients had successful SSR. No variables had a statistically significant association with successful SSR.
Onco-TESE represents a useful option for testis cancer patients who wish for future paternity, with a quarter of such patients having sperm found.
评估肿瘤睾丸精子提取术(TESE)的结果,并确定手术取精成功(SSR)的潜在预测因素。
在本研究中,我们检查了所有符合以下条件的男性:(i)被诊断患有睾丸肿块;(ii)无精子症;(iii)接受了根治性睾丸切除术和肿瘤TESE。我们查阅了机构的睾丸癌(TCA)患者数据库。记录了人口统计学信息、基线内分泌和肿瘤学特征以及接受的治疗。在将标本送去进行正式组织病理学评估之前,在根治性睾丸切除术时进行肿瘤TESE技术操作。如果发现有活力的精子,则认为肿瘤TESE成功。进行逻辑回归评估以评估肿瘤TESE成功的预测因素。
38名中位年龄为35岁的男性纳入分析。基线总睾酮、促黄体生成素(LH)和促卵泡生成素(FSH)水平的中位数分别为419ng/dL、10.9mU/mL和27mU/mL。TESE前睾丸体积的中位数为11 mL。在接受根治性睾丸切除术的男性中,58%在手术时患有单侧肿瘤。42%患有双侧肿瘤,其中25%为同步肿瘤,75%为异时肿瘤。病理上,76%患有生殖细胞肿瘤(83%为纯精原细胞瘤,17%为混合生殖细胞肿瘤)。在肿瘤TESE时,24%的患者SSR成功。没有变量与SSR成功有统计学上的显著关联。
肿瘤TESE对于希望未来生育的睾丸癌患者是一种有用的选择,四分之一的此类患者能找到精子。